December 8, 2025Blood

Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis shows obesity, age, and WBC count are relapse risk factors in B-ALL, highlighting poor survival post-relapse.

The study aims to identify risk factors for relapse and post-relapse outcomes in B-ALL treated with Blinatumomab.
Retrospective study of patients with Philadelphia chromosome-negative B-ALL receiving Blinatumomab-based regimens.
Assessment of relapse through univariate and multivariate analysis using competing risk regression model.
Evaluation of risk factors like obesity and TP53 mutations related to relapse outcomes.
239 patients received frontline Blinatumomab-based chemotherapy.
3-year cumulative incidence of relapse was 13%.
Multivariate analysis identified obesity and high white blood cell count as significant risk factors for relapse.

Arora et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark